Our Business

DVP EU markets and sells Dechra’s products in 19 countries: Austria, Belgium, Bosnia & Hertz, Croatia, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden and the UK.

In total, DVP EU employs 511 people, as field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, and technical support staff. Inventory is managed through a central distribution centre in Uldum.

The key products in the DVP EU portfolio are predominantly Companion Animal Products (CAP), Equine medicines and Food producing Animal Products (FAP). DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded Specific™.

DVP International was established as a separate commercial division in 2017, with the aim of further developing Dechra’s global brand and product offering. It markets and sells Dechra’s veterinary products in Australia, New Zealand and Brazil through our own legal entities and via distributors to 72 countries worldwide. DVP International has 90 employees excluding those employees in the Australian and Brazilian Manufacturing facilities.

DVP ANZ was established in 2016. It manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand. Following the acquisition in 2021 of the marketing rights to Tri-Solfen, the business will establish a farm animal business unit to deliver products and support for welfare in farm animal production.

DVP Brazil was acquired in 2018. It predominately manufactures, markets and sells vaccines in Brazil, other South American markets and some Asian countries.  We are currently registering Dechra’s leading companion animal brands.

Dechra International distributes its leading FAP, CAP, nutrition and poultry vaccine products to its key customers in most global markets. Through offering technical service and marketing support we help our customers establish our key brands and with the support of regulatory services we register and introduce new products to meet market needs.

DVP NA markets and sells Dechra’s veterinary products across Canada, Mexico and the US, the latter being the world’s largest animal health market.

The US business is located in Kansas City, at the heart of the ‘Animal Health Corridor’, an area recognised globally for its concentration of animal health businesses. There is also an additional office in Portland, Maine where part of the Product Development is based and a number of tele-sales.

DVP NA has 246 employees, who consist of field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, technical support staff and a customer service team. DVP US and Canada currently markets CAP and Equine medicines.

DVP Canada was established in January 2015 and the office is located in Montreal.

DVP Mexico, was acquired in January 2016. It markets CAP, FAP and Equine medicines, mainly in Mexico and also exports to Central American countries.

The Product Development team develops Dechra’s own branded veterinary product portfolio of novel, generic and generic plus pharmaceuticals and related medical products. The Regulatory Affairs team obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences.

A total of 159 people work across European and US Regulatory Affairs, Pharmaceutical Development and Product Development. The Regulatory Affairs team work at seven locations:

• Overland Park (Kansas) and Portland (Maine), USA;
• Sansaw (Shropshire) and Skipton (North Yorkshire), England;
• Bladel, the Netherlands;
• Zagreb, Croatia; and
• Mexico City, Mexico.

The Product Development team run in field clinical trials and formulate at three laboratories based at our manufacturing facilities.

The team includes highly qualified academics, veterinarians, formulation chemists, pharmacists, analysts, clinical trial managers and product development managers.

DPM produces approximately 40% of Dechra’s pharmaceuticals and manufactures for a limited number of third parties on a contract basis. It’s objectives are to produce Dechra’s product range efficiently to the highest quality standards, to maintain a reliable supply chain and to contribute profit to the business through third party manufacturing.

A total of 876 employees work in Manufacturing.

Skipton, Bladel and Zagreb sites include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.

Skipton, UK

The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.

Bladel, the Netherlands

The site at Bladel manufactures water soluble powder and premix  products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.

Zagreb, Croatia

It produces and develops egg based vaccines. It also produces liquids in various scales and formats and is currently being expanded to be a second source of solid dose tablets.

Fort Worth, Texas USA

This site manufactures solid dose, liquids, creams and ointments for the North American market.

Melbourne, Florida USA

It is a centre of excellence in manufacturing palatable and chewable tablets.

The following manufacturing sites are managed by our DVP International business:

Londrina, Brazil

This site produces a wide range of vaccines for multi species predominately for South America and selected export markets.

Sydney, Australia

This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.